Recent advancements in the pharmacological treatment of MASLD and MASH have shown promising results, particularly with medications such as Resmetirom and Fibroblast Growth Factor 21 (FGF21) analogs. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.